Botox in Psychiatry: Where the Evidence Actually Is

Botulinum toxin, sold as Botox and under several other brand names, blocks the chemical signal that nerves use to switch on muscles and sweat glands. Injected in small, carefully placed doses, it weakens one specific muscle or quietens one specific gland for roughly three months, after which the effect wears off and the injection has to be repeated if the benefit is to continue.

Two things follow. First, it is a local treatment. It acts where it is placed, not on the brain as a whole. Second, whatever it does, it does temporarily. Every claim made about botulinum toxin should be read with both of those facts in view.

The medicine holds licences across several specialties, including muscle spasticity, cervical dystonia, overactive bladder, severe underarm sweating, and chronic migraine. Its relevance to psychiatry comes from a small number of those uses, and from research that has not yet earned an approval.

This is the one use with a licence, a defined protocol, and trial evidence behind it, and it is the one offered in this practice.

Botulinum toxin was approved in 2010 for preventing headaches in adults with chronic migraine. Chronic migraine has a precise definition: headache on 15 or more days a month, each lasting four hours or longer, sustained over months. That is a considerably heavier burden than most people picture when they hear the word migraine, and it is the reason the treatment is not simply offered to anyone with bad headaches.

The treatment follows a fixed protocol developed in the PREEMPT trials: 155 units, divided across 31 injection sites, in seven muscle areas of the head and neck, repeated every twelve weeks. It is not a painkiller taken during an attack. It is a preventive treatment, judged over two or three cycles by whether the number of headache days actually falls.

The limits matter as much as the indication. Botulinum toxin is not approved for episodic migraine, meaning 14 or fewer headache days a month, and the placebo-controlled studies in that group did not establish benefit. It is not a treatment for tension-type headache. And it does not replace the ordinary work of headache care: identifying triggers, correcting sleep, and, very often, withdrawing the painkillers that have quietly become the problem.

Why any of this belongs in a psychiatry clinic rather than only a neurology one is a fair question. Depression occurs roughly twice as often in people with migraine as in the general population. Anxiety rises as headache frequency rises. Panic disorder is two to three times more common in chronic migraine than in the episodic form. The relationship runs in both directions, and reviews of this literature consistently find that managing the headache and the mood or anxiety disorder together works better than managing either alone. Someone with twenty headache days a month, broken sleep, and six months of flattened mood does not have two unrelated problems to be handled by two clinicians who never speak to each other.

In this practice, Botox for chronic migraine is given in person in New Delhi, after an assessment that establishes the diagnosis and excludes the causes that need something else entirely. The consultation itself can begin online.

Botulinum toxin is licensed for severe underarm sweating that has not responded to topical treatment, and for that purpose it works well. The psychiatric interest, though, is narrower than it first sounds.

In a placebo-controlled trial of 40 adults who had social anxiety disorder together with heavy sweating, everyone received an antidepressant and half also received botulinum toxin injections. Sweating improved in 75 per cent of the injected group against 15 per cent on placebo, and ratings of work and social functioning improved alongside it.

Read carefully, that is a study about removing a symptom that feeds social fear, not about treating the fear itself. Someone who avoids meetings because they can feel themselves sweating through a shirt may find a great deal changes when the sweating stops. Someone whose social anxiety has nothing to do with sweating has no particular reason to expect anything from it. There is also a loop worth knowing about: several antidepressants cause sweating in their own right, so the first question is often whether the medication is the source rather than the illness.

Bruxism, the grinding and clenching of teeth, is common in people under sustained stress and is a recognised effect of SSRI and SNRI antidepressants. It reaches psychiatric practice regularly, usually as morning jaw ache, headache on waking, or a dentist's remark about worn teeth.

Injections into the masseter, the large muscle at the angle of the jaw, do reduce that muscle's activity, and some trials report less pain. But the evidence is thin. Around a dozen randomised trials exist, most with fewer than fifty participants, using different outcome measures, and mostly following patients for less than six months. Reviewers of this literature state plainly that the quality is not high enough to write guidelines from. It is not an approved use, and it is not a first step.

There is also a specific safety signal worth stating. Repeated injections into the chewing muscles have been associated with reduced bone quality in the jaw, examined both in imaging studies of adults who had the treatment and in a systematic review of that work. That is not cause for alarm about a single medically indicated injection, but it is a good reason not to treat repeated masseter injections as a casual habit.

Where the clenching began after an antidepressant was started, the sensible order is to review the drug and the dose first, consider a switch or one of the small number of medicines used specifically to counter this effect, and use a dental splint to protect the teeth. Injections belong later in that sequence, discussed with a dentist or oral medicine specialist, not at the start of it.

The most talked about idea, that an injection into the frown muscles can lift mood, is the least settled of them all. Several small trials have reported benefit, and the pooled effect looks large. The difficulty is that participants could usually tell whether they had received the real injection. In one analysis, about ninety per cent of patients and sixty per cent of the people rating their mood guessed the allocation correctly. In a condition where the placebo response is already large, that weakens the finding rather than confirming it.

Botulinum toxin is not approved for depression, and clinical guidelines do not recommend it. It is a real research question, not a treatment. The trials, the effect sizes, and why they are hard to interpret are set out in full in Botox for Depression: What the Research Shows.

A plausible mechanism is not evidence. Much of what circulates about botulinum toxin and mental health rests on the fact that the story makes sense, and stories that make sense are exactly the ones that get repeated before anyone checks them.

Three questions settle most of it. Is there a licensed indication for this particular use? Is there trial evidence, and could those trials realistically be kept blind? And is the thing being injected actually the thing causing the distress? Measured against those, chronic migraine passes clearly, severe sweating passes for the symptom it treats, jaw clenching is unsettled, and depression is not there yet.